EA200201104A1 - ПРЕПАРАТ, СОДЕРЖАЩИЙ ГЕМОСТАТИЧЕСКИ АКТИВНЫЙ ФАКТОР vWF, И СПОСОБ ЕГО ПОЛУЧЕНИЯ - Google Patents

ПРЕПАРАТ, СОДЕРЖАЩИЙ ГЕМОСТАТИЧЕСКИ АКТИВНЫЙ ФАКТОР vWF, И СПОСОБ ЕГО ПОЛУЧЕНИЯ

Info

Publication number
EA200201104A1
EA200201104A1 EA200201104A EA200201104A EA200201104A1 EA 200201104 A1 EA200201104 A1 EA 200201104A1 EA 200201104 A EA200201104 A EA 200201104A EA 200201104 A EA200201104 A EA 200201104A EA 200201104 A1 EA200201104 A1 EA 200201104A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vwf
obtaining
fraction
vego
preparation containing
Prior art date
Application number
EA200201104A
Other languages
English (en)
Other versions
EA006209B1 (ru
Inventor
Дьюро Йозик
Моника Штадлер
Герхард Грубер
Original Assignee
Октафарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Октафарма Аг filed Critical Октафарма Аг
Publication of EA200201104A1 publication Critical patent/EA200201104A1/ru
Publication of EA006209B1 publication Critical patent/EA006209B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Способ получения препарата, содержащего гемостатически активный фактор Виллебранда (vWF), из фракции человеческой плазмы посредством хроматографической очистки фракции плазмы, содержащей vWF, на анионообменном материале, характеризующимся анионообменными группами на привитых полимерных структурах (Tentakel-материалы), накопления фракции, содержащей vWF, последующей очистки этой фракции посредством гельпроникающей хроматографии для получения препарата, содержащего очищенный термостабильный фактор vWF, и нагревания препарата для инактивации вирусов.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200201104A 2000-04-18 2001-04-04 ПРЕПАРАТ, СОДЕРЖАЩИЙ ГЕМОСТАТИЧЕСКИ АКТИВНЫЙ ФАКТОР vWF, И СПОСОБ ЕГО ПОЛУЧЕНИЯ EA006209B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00108430A EP1148063A1 (de) 2000-04-18 2000-04-18 Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
PCT/EP2001/003819 WO2001079260A1 (de) 2000-04-18 2001-04-04 Haemostatisch aktives vwf enthaltendes präparat und verfahren zu seiner herstellung

Publications (2)

Publication Number Publication Date
EA200201104A1 true EA200201104A1 (ru) 2003-04-24
EA006209B1 EA006209B1 (ru) 2005-10-27

Family

ID=8168496

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200201104A EA006209B1 (ru) 2000-04-18 2001-04-04 ПРЕПАРАТ, СОДЕРЖАЩИЙ ГЕМОСТАТИЧЕСКИ АКТИВНЫЙ ФАКТОР vWF, И СПОСОБ ЕГО ПОЛУЧЕНИЯ

Country Status (24)

Country Link
US (2) US7166709B2 (ru)
EP (2) EP1148063A1 (ru)
JP (1) JP4976634B2 (ru)
KR (1) KR100685448B1 (ru)
CN (1) CN100448888C (ru)
AT (1) ATE306494T1 (ru)
AU (2) AU6383501A (ru)
BR (1) BR0110193A (ru)
CA (1) CA2406626C (ru)
CZ (1) CZ303932B6 (ru)
DE (1) DE50107689D1 (ru)
DK (1) DK1274721T3 (ru)
EA (1) EA006209B1 (ru)
EE (1) EE200200595A (ru)
ES (1) ES2247117T3 (ru)
HU (1) HU225992B1 (ru)
IL (2) IL152173A0 (ru)
MX (1) MXPA02010017A (ru)
NO (1) NO324773B1 (ru)
RS (1) RS50835B (ru)
SI (1) SI1274721T1 (ru)
UA (1) UA76714C2 (ru)
WO (1) WO2001079260A1 (ru)
ZA (1) ZA200208396B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
ITLU20070007A1 (it) * 2007-05-07 2008-11-08 Kedrion Spa Processo cromatografico per l'ottenimento di un complesso fviii/vwf con differenti rapporti tra le due proteine da utilizzare nella terapia della emofilia a e nella malattia di von willebrand.
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
BRPI0821474B8 (pt) 2007-12-28 2021-05-25 Baxalta GmbH formulação farmacêutica líquida estável
KR101507718B1 (ko) 2008-06-24 2015-04-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
TWI508735B (zh) 2008-10-21 2015-11-21 巴克斯特國際公司 凍乾的重組ｖｗｆ調配物
IT1396528B1 (it) * 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
CA2801116C (en) * 2010-06-01 2019-02-12 Baxter International Inc. Process for making dry and stable hemostatic compositions
US9371355B2 (en) 2010-09-20 2016-06-21 Octapharma Ag Process for production of fibrinogen
US9488625B2 (en) 2010-12-15 2016-11-08 Baxalta GmbH Purification of factor VIII using a conductivity gradient
US10064406B2 (en) * 2011-01-06 2018-09-04 Cytosorbents Corporation Polymeric sorbent for removal of impurities from whole blood and blood products
CN104321340B (zh) 2012-03-13 2018-11-09 欧克塔医药公司 用于生产纤维蛋白原的改进工艺及其生产的纤维蛋白原
CN104411716B (zh) 2012-04-24 2018-09-07 诺和诺德股份有限公司 适用于治疗血友病的化合物
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
ES2053684T3 (es) 1988-11-05 1994-08-01 Octapharma Ag Procedimiento para preparar un factor antihemofilico, altamente puro, no infeccioso, mediante cromatografia.
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
FR2681867B1 (fr) * 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
DE4204694C3 (de) * 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
JP3133338B2 (ja) * 1992-12-16 2001-02-05 イムノ・アクチエンゲゼルシャフト ウイルス的に安全な生物学的組成物の調製方法
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT404358B (de) * 1997-02-04 1998-11-25 Immuno Ag Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
US6531577B1 (en) * 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
AU6383501A (en) 2001-10-30
CZ20023454A3 (cs) 2003-05-14
BR0110193A (pt) 2003-02-11
MXPA02010017A (es) 2003-04-25
US7166709B2 (en) 2007-01-23
HUP0301211A3 (en) 2005-12-28
US7985846B2 (en) 2011-07-26
US20030138913A1 (en) 2003-07-24
EP1274721B1 (de) 2005-10-12
AU2001263835B2 (en) 2005-06-09
CA2406626A1 (en) 2001-10-25
NO20025007D0 (no) 2002-10-17
CN100448888C (zh) 2009-01-07
UA76714C2 (ru) 2006-09-15
ZA200208396B (en) 2004-04-30
ES2247117T3 (es) 2006-03-01
CA2406626C (en) 2012-02-21
ATE306494T1 (de) 2005-10-15
EP1274721A1 (de) 2003-01-15
NO324773B1 (no) 2007-12-10
KR100685448B1 (ko) 2007-02-23
JP2004516231A (ja) 2004-06-03
HUP0301211A2 (hu) 2003-07-28
CN1425024A (zh) 2003-06-18
HU225992B1 (en) 2008-02-28
SI1274721T1 (sl) 2006-04-30
IL152173A (en) 2007-07-24
PL358388A1 (en) 2004-08-09
EP1148063A1 (de) 2001-10-24
DK1274721T3 (da) 2006-02-13
JP4976634B2 (ja) 2012-07-18
IL152173A0 (en) 2003-05-29
CZ303932B6 (cs) 2013-07-03
EE200200595A (et) 2004-04-15
YU78402A (sh) 2006-08-17
RS50835B (sr) 2010-08-31
US20070232791A1 (en) 2007-10-04
KR20030019352A (ko) 2003-03-06
NO20025007L (no) 2002-11-28
EA006209B1 (ru) 2005-10-27
WO2001079260A1 (de) 2001-10-25
DE50107689D1 (de) 2006-02-23

Similar Documents

Publication Publication Date Title
EA200201104A1 (ru) ПРЕПАРАТ, СОДЕРЖАЩИЙ ГЕМОСТАТИЧЕСКИ АКТИВНЫЙ ФАКТОР vWF, И СПОСОБ ЕГО ПОЛУЧЕНИЯ
BR0013231A (pt) Complexos citocina-anticorpo múltiplos
EP1200124A4 (en) IMMUNOGLOBIN FUSION PROTEINS
MA26463A1 (fr) Nouvelles sulfones cycliques, leur procede de production et composition pharmaceutique les contenant
ID23374A (id) Halogenopirimidin
DE59607712D1 (de) Vernetzbare, photoaktive Polymermaterialien
DE3762867D1 (de) Mesomorpher polymerwirkstoff, verwendungsfaehig zur nichtlinearoptik.
FR2681326B1 (fr) Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments.
DZ2702A1 (fr) Nouveaux amides aromatiques leur procédé de préparation et leur application comme médicaments.
DE69007371D1 (de) Polymerzusammensetzung, Klebemittel und etikettiertes Glasmaterial.
MY116595A (en) Polycarboxylic based cross-linked copolymers
ATE195124T1 (de) Kondensierte pyrrolo(2,3-c) carbazole-6-one die die aktivität von gamma interferon potenzieren
ES2078971T3 (es) Produccion de virus y purificacion de proteinas con envoltura virica para uso en vacunas.
DK0775159T3 (da) Ny fremgangsmåde til fremstilling af biologisk aktivt dimert protein
YU12397A (en) NOVEL PYRIMIDO [1,2-a] INDOLES
FR2658187B1 (fr) Nouveaux acides alpha-hydroxyles, procede de preparation et leur utilisation.
NO20006181L (no) Ekspresjonsvektor
DK0815141T3 (da) Antistof mod et fusionspolypeptid omfattende en histidinandel
DE3769438D1 (de) Wanderfeldroehre mit periodisch-permanentmagnetischem fokussiersystem.
IT1286761B1 (it) Procedimento di produzione di stoppini per contenitori di soluzioni vaporizzabili, in particolare soluzioni insetticide.
FR2741087B1 (fr) Complexe proteique dodecaedrique adenoviral, procede de preparation, composition le contenant et ses applications
SE9600213L (sv) Förfarande för storleksfraktionering av molekyler med hög molekylvikt, med användande av elektroosmotiskt flöde i en kapillärtub
FI855149A0 (fi) Nya n-(2-hydroxialkyl)aminosyror och deras derivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska preparat.
FR2681598B1 (fr) Nouveaux derives de la decahydroquinoleine, leur procede de preparation, les intermediaires de preparation, leur application a titre de medicaments et les compositions les renfermant.
ITRM940091A0 (it) Procedimento per la preparazione di colture cellulari di eisenia foetida (anellidi, oligocheti).

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU